Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Small-molecule BCL6 inhibitor effectively treats mice with non-sclerodermatous chronic graft-versus-host disease.

Paz K, Flynn R, Du J, Qi J, Luznik L, Maillard I, MacDonald KP, Hill GR, Serody JS, Murphy WJ, Sage PT, Sharpe AH, Miklos D, Culter CS, Koreth J, Antin JH, Soiffer RJ, Ritz J, Bradner JE, Melnick AM, Blazar B.

Blood. 2018 Oct 2. pii: blood-2018-03-839993. doi: 10.1182/blood-2018-03-839993. [Epub ahead of print]

PMID:
30279226
2.

TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis.

Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Béguelin W, Fontan L, Rivas MA, Pawlikowska P, Armand M, Mouly E, Torres-Martin M, Doane AS, Calvo Fernandez MT, Durant M, Della-Valle V, Teater M, Cimmino L, Droin N, Tadros S, Motanagh S, Shih AH, Rubin MA, Tam W, Aifantis I, Levine RL, Elemento O, Inghirami G, Green MR, Figueroa ME, Bernard OA, Aoufouchi S, Li S, Shaknovich R, Melnick AM.

Cancer Discov. 2018 Oct 1. pii: CD-18-0657. doi: 10.1158/2159-8290.CD-18-0657. [Epub ahead of print]

PMID:
30274972
3.

PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival.

Lu X, Fernando TM, Lossos C, Yusufova N, Liu F, Fontán L, Durant M, Geng H, Melnick J, Luo Y, Vega F, Moy V, Inghirami G, Nimer S, Melnick AM, Lossos IS.

Blood. 2018 Nov 8;132(19):2026-2039. doi: 10.1182/blood-2018-02-831438. Epub 2018 Aug 6.

PMID:
30082494
4.

Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells.

Purwada A, Shah SB, Béguelin W, August A, Melnick AM, Singh A.

Biomaterials. 2018 Jun 26. pii: S0142-9612(18)30461-7. doi: 10.1016/j.biomaterials.2018.06.034. [Epub ahead of print]

PMID:
30041943
5.

How Biophysical Forces Regulate Human B Cell Lymphomas.

Apoorva F, Loiben AM, Shah SB, Purwada A, Fontan L, Goldstein R, Kirby BJ, Melnick AM, Cosgrove BD, Singh A.

Cell Rep. 2018 Apr 10;23(2):499-511. doi: 10.1016/j.celrep.2018.03.069.

6.

Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs.

Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD.

Mol Cell. 2018 Feb 1;69(3):533. doi: 10.1016/j.molcel.2018.01.014. No abstract available.

7.

EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop.

Béguelin W, Rivas MA, Calvo Fernández MT, Teater M, Purwada A, Redmond D, Shen H, Challman MF, Elemento O, Singh A, Melnick AM.

Nat Commun. 2017 Oct 12;8(1):877. doi: 10.1038/s41467-017-01029-x.

8.

Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.

Oricchio E, Katanayeva N, Donaldson MC, Sungalee S, Pasion JP, Béguelin W, Battistello E, Sanghvi VR, Jiang M, Jiang Y, Teater M, Parmigiani A, Budanov AV, Chan FC, Shah SP, Kridel R, Melnick AM, Ciriello G, Wendel HG.

Sci Transl Med. 2017 Jun 28;9(396). pii: eaak9969. doi: 10.1126/scitranslmed.aak9969.

9.

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2025. doi: 10.1126/scitranslmed.aaj2025.

10.

The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target.

Cardenas MG, Oswald E, Yu W, Xue F, MacKerell AD Jr, Melnick AM.

Clin Cancer Res. 2017 Feb 15;23(4):885-893. doi: 10.1158/1078-0432.CCR-16-2071. Epub 2016 Nov 23. Review.

11.

DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.

Guryanova OA, Shank K, Spitzer B, Luciani L, Koche RP, Garrett-Bakelman FE, Ganzel C, Durham BH, Mohanty A, Hoermann G, Rivera SA, Chramiec AG, Pronier E, Bastian L, Keller MD, Tovbin D, Loizou E, Weinstein AR, Gonzalez AR, Lieu YK, Rowe JM, Pastore F, McKenney AS, Krivtsov AV, Sperr WR, Cross JR, Mason CE, Tallman MS, Arcila ME, Abdel-Wahab O, Armstrong SA, Kubicek S, Staber PB, Gönen M, Paietta EM, Melnick AM, Nimer SD, Mukherjee S, Levine RL.

Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.

12.

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain.

Nandi S, Chandramohan D, Fioriti L, Melnick AM, Hébert JM, Mason CE, Rajasethupathy P, Kandel ER.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12697-12702. doi: 10.1073/pnas.1609287113. Epub 2016 Oct 24.

13.

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas.

Jiang Y, Ortega-Molina A, Geng H, Ying HY, Hatzi K, Parsa S, McNally D, Wang L, Doane AS, Agirre X, Teater M, Meydan C, Li Z, Poloway D, Wang S, Ennishi D, Scott DW, Stengel KR, Kranz JE, Holson E, Sharma S, Young JW, Chu CS, Roeder RG, Shaknovich R, Hiebert SW, Gascoyne RD, Tam W, Elemento O, Wendel HG, Melnick AM.

Cancer Discov. 2017 Jan;7(1):38-53. doi: 10.1158/2159-8290.CD-16-0975. Epub 2016 Oct 12.

14.

Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.

Bunting KL, Soong TD, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M, Elemento O, Melnick AM.

Immunity. 2016 Sep 20;45(3):497-512. doi: 10.1016/j.immuni.2016.08.012. Epub 2016 Sep 13.

15.

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

Béguelin W, Teater M, Gearhart MD, Calvo Fernández MT, Goldstein RL, Cárdenas MG, Hatzi K, Rosen M, Shen H, Corcoran CM, Hamline MY, Gascoyne RD, Levine RL, Abdel-Wahab O, Licht JD, Shaknovich R, Elemento O, Bardwell VJ, Melnick AM.

Cancer Cell. 2016 Aug 8;30(2):197-213. doi: 10.1016/j.ccell.2016.07.006.

16.

SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents.

Fiskus W, Coothankandaswamy V, Chen J, Ma H, Ha K, Saenz DT, Krieger SS, Mill CP, Sun B, Huang P, Mumm JS, Melnick AM, Bhalla KN.

Cancer Res. 2016 Sep 15;76(18):5467-78. doi: 10.1158/0008-5472.CAN-16-0126. Epub 2016 Aug 8.

17.

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang SN, Cohen J, Shaknovich R, Vanommeslaeghe K, Cheng H, Liang D, Cho HJ, Abbott J, Tam W, Du W, Leonard JP, Elemento O, Cerchietti L, Cierpicki T, Xue F, MacKerell AD Jr, Melnick AM.

J Clin Invest. 2016 Sep 1;126(9):3351-62. doi: 10.1172/JCI85795. Epub 2016 Aug 2.

18.

A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations.

Han D, Lu X, Shih AH, Nie J, You Q, Xu MM, Melnick AM, Levine RL, He C.

Mol Cell. 2016 Aug 18;63(4):711-719. doi: 10.1016/j.molcel.2016.06.028. Epub 2016 Jul 28.

19.

A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.

Luskin MR, Gimotty PA, Smith C, Loren AW, Figueroa ME, Harrison J, Sun Z, Tallman MS, Paietta EM, Litzow MR, Melnick AM, Levine RL, Fernandez HF, Luger SM, Carroll M, Master SR, Wertheim GB.

JCI Insight. 2016 Jun 16;1(9). pii: e87323.

20.

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.

Garrett-Bakelman FE, Melnick AM.

Epigenomics. 2016 Jul;8(7):945-57. doi: 10.2217/epi-2016-0008. Epub 2016 Jul 19. Review.

21.

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE.

Nat Med. 2016 Jul;22(7):792-9. doi: 10.1038/nm.4125. Epub 2016 Jun 20.

22.

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martin-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sanchez E, Cobaleda C, Sanchez-Garcia I, Fernandez-Luna JL, Garcia-Muñoz R, Pena E, Bellosillo B, Salar A, Baptista MJ, Hernandez-Rivas JM, Gonzalez M, Terol MJ, Climent J, Ferrandez A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martinez-Climent JA.

Nat Commun. 2016 Jun 14;7:11889. doi: 10.1038/ncomms11889.

23.

The many layers of epigenetic dysfunction in B-cell lymphomas.

Jiang Y, Dominguez PM, Melnick AM.

Curr Opin Hematol. 2016 Jul;23(4):377-84. doi: 10.1097/MOH.0000000000000249. Review.

PMID:
27055146
24.

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma.

Jiang Y, Nie K, Redmond D, Melnick AM, Tam W, Elemento O.

J Vis Exp. 2015 Dec 28;(106):e53215. doi: 10.3791/53215.

25.

Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.

Guryanova OA, Lieu YK, Garrett-Bakelman FE, Spitzer B, Glass JL, Shank K, Martinez AB, Rivera SA, Durham BH, Rapaport F, Keller MD, Pandey S, Bastian L, Tovbin D, Weinstein AR, Teruya-Feldstein J, Abdel-Wahab O, Santini V, Mason CE, Melnick AM, Mukherjee S, Levine RL.

Leukemia. 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29.

26.

Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.

Tian YF, Ahn H, Schneider RS, Yang SN, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.

Biomaterials. 2015 Dec;73:110-9. doi: 10.1016/j.biomaterials.2015.09.007. Epub 2015 Sep 11.

27.

The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development.

Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, Jiang M, Hu D, Agirre X, Niesvizky I, Lee JE, Chen HT, Ennishi D, Scott DW, Mottok A, Hother C, Liu S, Cao XJ, Tam W, Shaknovich R, Garcia BA, Gascoyne RD, Ge K, Shilatifard A, Elemento O, Nussenzweig A, Melnick AM, Wendel HG.

Nat Med. 2015 Oct;21(10):1199-208. doi: 10.1038/nm.3943. Epub 2015 Sep 14.

28.

Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs.

Noh KM, Wang H, Kim HR, Wenderski W, Fang F, Li CH, Dewell S, Hughes SH, Melnick AM, Patel DJ, Li H, Allis CD.

Mol Cell. 2015 Jul 2;59(1):89-103. doi: 10.1016/j.molcel.2015.05.017. Epub 2015 Jun 11. Erratum in: Mol Cell. 2018 Feb 1;69(3):533.

29.

VII. Are lymphomas driven by epigenetic lesions?

Boss IW, Melnick AM.

Hematol Oncol. 2015 Jun;33 Suppl 1:42-5. doi: 10.1002/hon.2215. Review. No abstract available.

PMID:
26062053
30.

Epigenomic evolution in diffuse large B-cell lymphomas.

Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R, Melnick AM, Inghirami GG, Tam W, Elemento O.

Nat Commun. 2015 Apr 20;6:6921. doi: 10.1038/ncomms7921.

31.

A roadmap for discovery and translation in lymphoma.

Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM.

Blood. 2015 Mar 26;125(13):2175-7. doi: 10.1182/blood-2015-01-623777. No abstract available.

32.

Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution.

Garrett-Bakelman FE, Sheridan CK, Kacmarczyk TJ, Ishii J, Betel D, Alonso A, Mason CE, Figueroa ME, Melnick AM.

J Vis Exp. 2015 Feb 24;(96):e52246. doi: 10.3791/52246.

33.

The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.

Van der Meulen J, Sanghvi V, Mavrakis K, Durinck K, Fang F, Matthijssens F, Rondou P, Rosen M, Pieters T, Vandenberghe P, Delabesse E, Lammens T, De Moerloose B, Menten B, Van Roy N, Verhasselt B, Poppe B, Benoit Y, Taghon T, Melnick AM, Speleman F, Wendel HG, Van Vlierberghe P.

Blood. 2015 Jan 1;125(1):13-21. doi: 10.1182/blood-2014-05-577270. Epub 2014 Oct 15.

34.

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.

Jiang Y, Redmond D, Nie K, Eng KW, Clozel T, Martin P, Tan LH, Melnick AM, Tam W, Elemento O.

Genome Biol. 2014 Aug 15;15(8):432. doi: 10.1186/s13059-014-0432-0.

35.

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.

Oncotarget. 2014 Jul 30;5(14):5637-50.

36.

Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O.

Sci Transl Med. 2014 May 28;6(238):238ra71. doi: 10.1126/scitranslmed.3008004.

37.

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):E2219-28. doi: 10.1073/pnas.1400958111. Epub 2014 May 12.

38.

High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.

Kuo PY, Leshchenko VV, Fazzari MJ, Perumal D, Gellen T, He T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh KS, Goy A, Yang DT, Chan WC, Kahl BS, Verma AK, Gascoyne RD, Kimby E, Sander B, Ye BH, Melnick AM, Parekh S.

Oncogene. 2015 Mar 5;34(10):1231-40. doi: 10.1038/onc.2014.44. Epub 2014 Mar 31.

39.

Differentiation therapy for IDH1/2 mutant malignancies.

Garrett-Bakelman FE, Melnick AM.

Cell Res. 2013 Aug;23(8):975-7. doi: 10.1038/cr.2013.73. Epub 2013 Jun 4.

40.

New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes.

Bunting KL, Melnick AM.

Curr Opin Immunol. 2013 Jun;25(3):339-46. doi: 10.1016/j.coi.2013.05.003. Epub 2013 May 30. Review.

41.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T, Martinez-Garcia E, Zhang H, Zheng Y, Verma SK, McCabe MT, Ott HM, Van Aller GS, Kruger RG, Liu Y, McHugh CF, Scott DW, Chung YR, Kelleher N, Shaknovich R, Creasy CL, Gascoyne RD, Wong KK, Cerchietti L, Levine RL, Abdel-Wahab O, Licht JD, Elemento O, Melnick AM.

Cancer Cell. 2013 May 13;23(5):677-92. doi: 10.1016/j.ccr.2013.04.011.

42.

BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements.

Lu Z, Tsai AG, Akasaka T, Ohno H, Jiang Y, Melnick AM, Greisman HA, Lieber MR.

Blood. 2013 May 30;121(22):4551-4. doi: 10.1182/blood-2012-10-464958. Epub 2013 Mar 8.

43.

Notch activation inhibits AML growth and survival: a potential therapeutic approach.

Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME, Zweidler-McKay PA.

J Exp Med. 2013 Feb 11;210(2):321-37. doi: 10.1084/jem.20121527. Epub 2013 Jan 28.

44.

Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.

Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.

Leukemia. 2013 Apr;27(4):852-60. doi: 10.1038/leu.2012.363. Epub 2012 Dec 13.

45.

Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H, Melnick AM, Elemento O, Demichelis F, Rubin MA.

Cancer Res. 2013 Feb 1;73(3):1232-44. doi: 10.1158/0008-5472.CAN-12-2968. Epub 2012 Dec 11.

46.

Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM.

Cancer Discov. 2012 Nov;2(11):1004-23. doi: 10.1158/2159-8290.CD-12-0208. Epub 2012 Oct 29.

47.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Nischal S, Bhattacharyya S, Christopeit M, Yu Y, Zhou L, Bhagat TD, Sohal D, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski JP, Melnick AM, Greally JM, Steidl U, Moliterno A, Verma A.

Cancer Res. 2013 Feb 1;73(3):1076-85. doi: 10.1158/0008-5472.CAN-12-0735. Epub 2012 Oct 11.

48.

Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling.

Park-Min KH, Lee EY, Moskowitz NK, Lim E, Lee SK, Lorenzo JA, Huang C, Melnick AM, Purdue PE, Goldring SR, Ivashkiv LB.

J Bone Miner Res. 2013 Jan;28(1):135-49. doi: 10.1002/jbmr.1739.

49.

Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.

Jiang Y, Soong TD, Wang L, Melnick AM, Elemento O.

PLoS One. 2012;7(7):e40332. doi: 10.1371/journal.pone.0040332. Epub 2012 Jul 12.

50.

Oncogene-mediated alterations in chromatin conformation.

Rickman DS, Soong TD, Moss B, Mosquera JM, Dlabal J, Terry S, MacDonald TY, Tripodi J, Bunting K, Najfeld V, Demichelis F, Melnick AM, Elemento O, Rubin MA.

Proc Natl Acad Sci U S A. 2012 Jun 5;109(23):9083-8. doi: 10.1073/pnas.1112570109. Epub 2012 May 21.

Supplemental Content

Loading ...
Support Center